Cutler Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-23,400
| Closed | -$161K | – | 3959 |
|
|
2023
Q4 | $161K | Buy |
+23,400
| New | +$1.32M | 0.01% | 845 |
|
|
2023
Q1 | – | Sell |
-5,300
| Closed | -$1K | – | 4977 |
|
|
2022
Q4 | $1K | Buy |
5,300
+500
| +10% | +$32.4K | ﹤0.01% | 4240 |
|
|
2022
Q3 | $17K | Buy |
4,800
+1,100
| +30% | +$81.4K | ﹤0.01% | 2744 |
|
|
2022
Q2 | $18K | Buy |
3,700
+100
| +3% | +$6.36K | ﹤0.01% | 2773 |
|
|
2022
Q1 | $13K | Sell |
3,600
-19,300
| -84% | -$1.97M | ﹤0.01% | 3431 |
|
|
2021
Q4 | $30K | Sell |
22,900
-45,000
| -66% | -$6.99M | ﹤0.01% | 2816 |
|
|
2021
Q3 | $80K | Buy |
+67,900
| New | +$10.9M | ﹤0.01% | 2114 |
|
|
2021
Q2 | – | Sell |
-10,900
| Closed | -$35K | – | 6566 |
|
|
2021
Q1 | $35K | Buy |
10,900
+1,300
| +14% | +$257K | ﹤0.01% | 2717 |
|
|
2020
Q4 | $117K | Buy |
9,600
+3,200
| +50% | +$692K | 0.01% | 1426 |
|
|
2020
Q3 | $95K | Buy |
6,400
+4,900
| +327% | +$671K | 0.01% | 1355 |
|
|
2020
Q2 | $14K | Sell |
1,500
-35,400
| -96% | -$3.43M | ﹤0.01% | 2656 |
|
|
2020
Q1 | $74K | Buy |
36,900
+13,700
| +59% | +$1.23M | ﹤0.01% | 1516 |
|
|
2019
Q4 | $516K | Sell |
23,200
-18,300
| -44% | -$1.77M | 0.03% | 442 |
|
|
2019
Q3 | $142K | Buy |
41,500
+13,500
| +48% | +$1.27M | 0.01% | 871 |
|
|
2019
Q2 | $215K | Buy |
28,000
+9,400
| +51% | +$732K | 0.02% | 677 |
|
|
2019
Q1 | $184K | Buy |
+18,600
| New | +$1.27M | 0.02% | 684 |
|
|
2018
Q4 | – | Sell |
-56,700
| Closed | -$111K | – | 4759 |
|
|
2018
Q3 | $111K | Buy |
56,700
+44,200
| +354% | +$2.46M | 0.01% | 1140 |
|
|
2018
Q2 | $88K | Buy |
12,500
+11,900
| +1,983% | +$449K | 0.01% | 1235 |
|
|
2018
Q1 | $5K | Sell |
600
-17,400
| -97% | -$483K | ﹤0.01% | 3339 |
|
|
2017
Q4 | $51K | Buy |
18,000
+14,700
| +445% | +$228K | ﹤0.01% | 1848 |
|
|
2017
Q3 | $12K | Buy |
+3,300
| New | +$19.1K | ﹤0.01% | 3669 |
|
|
2017
Q2 | – | Sell |
-18,800
| Closed | -$43K | – | 7279 |
|
|
2017
Q1 | $43K | Buy |
+18,800
| New | +$103K | ﹤0.01% | 2572 |
|
|
2016
Q4 | – | Sell |
-900
| Closed | -$1K | – | 7517 |
|
|
2016
Q3 | $1K | Buy |
+900
| New | +$4.79K | ﹤0.01% | 6374 |
|
|
2016
Q1 | – | Sell |
-600
| Closed | -$1K | – | 7393 |
|
|
2015
Q4 | $1K | Buy |
+600
| New | +$21.2K | ﹤0.01% | 6156 |
|
Other funds holding MRTX
Cutler Group's MRTX Position: Q1 2024 in Review
Cutler Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,500 shares — an estimated $88K sold.
Cutler Group first reported a position in MRTX in Q4 2015 and held it in 26 quarters. The position peaked at $3.6M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Cutler Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Cutler Group sold 1,500 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $88K.
- Cutler Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 26 quarters.
- Cutler Group's Mirati Therapeutics, Inc. Common Stock position peaked at $3.6M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.